On February 1st, Sanofi released its 2023 financial report, stating that its annual sales reached 43.07 billion euros (46.52 billion US dollars, equivalent to 1.08 US dollars at the current exchange rate), a year-on-year increase of 5.3%. The total revenue in the fourth quarter was 10.9 billion euros (11.77 billion US dollars), a year-on-year increase of 9.3%.
Specifically, in the full year of 2023, the company's pharmaceutical business revenue was 30.4 billion euros (32.83 billion US dollars); The vaccine business revenue was 7.5 billion euros (8.1 billion US dollars), a year-on-year increase of 8.3%; Consumer healthcare business revenue was 5.2 billion euros (5.62 billion US dollars), a year-on-year increase of 6.3%.
From the perspective of regional distribution of revenue, the US market remains Sanofi's main battlefield, contributing 18.512 billion euros (approximately 20.243 billion US dollars) in revenue, a year-on-year increase of 4.8%, a decrease from the 12.2% growth rate of the previous year; The Chinese market revenue is 2.912 billion euros (approximately 3.184 billion US dollars), and the growth rate has also slowed down (a year-on-year increase of 0.4% in 2023 and a year-on-year increase of 6.2% in the same period last year).
Thanks to the sustained release of clinical demand for atopic dermatitis, asthma, chronic sinusitis with nasal polyps, nodular prurigo, and eosinophilic esophagitis (EoE), Duprizumab has achieved tremendous success, supporting half of the specialty drug sector. In the fourth quarter, sales amounted to 2.99 billion euros (3.23 billion US dollars), and in 2023, sales reached 10.715 billion euros (11.57 billion US dollars). In November last year, the asthma indication of Duprizumab was officially approved in China. In addition, on January 25th this year, its EoE indication was approved by the FDA to fully cover children and adult patients, and sales are expected to further increase this year. Sanofi CEO Paul Hudson also stated that the sales of Duprizumab will reach 13 billion euros in 2024.
In 2023, Sanofi also contributed to the breakthrough progress in the field of respiratory syncytial virus (RSV). Its RSV neutralizing antibody, Beyfortus, developed in collaboration with AstraZeneca, has been fully launched in China, the United States, and Europe, providing a powerful tool for preventing RSV infection in infants and young children worldwide. As the only neutralizing antibody for infants and young children in the current RSV field, Beyfortus has achieved sales of 547 million euros (approximately 598 million US dollars).